- Home
- WKC vs SRPT Comparison
WKC vs SRPT Comparison
Compare WKC & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WKC | SRPT |
|---|---|---|
| Founded | 1984 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | WKC | SRPT |
|---|---|---|
| Price | $36.95 | $18.34 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 29 |
| Target Price | ★ $28.00 | $25.85 |
| AVG Volume (30 Days) | 1.4M | ★ 3.1M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.44 | ★ 2.99 |
| Revenue | ★ $36,916,600,000.00 | $2,198,237,000.00 |
| Revenue This Year | $0.62 | N/A |
| Revenue Next Year | $3.42 | N/A |
| P/E Ratio | $25.58 | ★ $6.09 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $22.21 | $14.68 |
| 52 Week High | $41.20 | $25.32 |
Technical Indicators
Market Signals| Indicator | WKC | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.28 | 62.63 |
| Support Level | $22.92 | $18.38 |
| Resistance Level | $37.88 | $19.25 |
| Average True Range (ATR) | 1.31 | 0.82 |
| MACD | -0.48 | 0.33 |
| Stochastic Oscillator | 22.08 | 100.00 |
Price Performance
Historical ComparisonAbout WKC World Kinect Corporation
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. It earns the majority of its revenue from the Aviation segment.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.